YHB Investment Advisors Inc. Sells 36,248 Shares of Kenvue Inc. (NYSE:KVUE)

YHB Investment Advisors Inc. decreased its holdings in Kenvue Inc. (NYSE:KVUE) by 41.9% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 50,240 shares of the company’s stock after selling 36,248 shares during the quarter. YHB Investment Advisors Inc.’s holdings in Kenvue were worth $1,073,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently bought and sold shares of KVUE. Grove Bank & Trust boosted its stake in shares of Kenvue by 438.4% in the fourth quarter. Grove Bank & Trust now owns 1,163 shares of the company’s stock valued at $25,000 after buying an additional 947 shares during the period. Geneos Wealth Management Inc. acquired a new position in Kenvue in the 4th quarter valued at $29,000. Riverview Trust Co bought a new stake in shares of Kenvue during the 3rd quarter valued at $30,000. Fortitude Family Office LLC increased its position in shares of Kenvue by 106.6% in the fourth quarter. Fortitude Family Office LLC now owns 1,506 shares of the company’s stock worth $32,000 after purchasing an additional 777 shares during the period. Finally, Ashton Thomas Securities LLC acquired a new position in Kenvue in the third quarter valued at about $35,000. Institutional investors own 97.64% of the company’s stock.

Kenvue Stock Performance

Kenvue stock opened at $21.36 on Wednesday. The business has a 50 day moving average of $22.05 and a 200-day moving average of $21.85. The company has a market capitalization of $40.95 billion, a P/E ratio of 38.84, a P/E/G ratio of 1.99 and a beta of 1.46. Kenvue Inc. has a 1 year low of $17.67 and a 1 year high of $24.46. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.00 and a quick ratio of 0.69.

Kenvue (NYSE:KVUE) last announced its quarterly earnings results on Thursday, November 7th. The company reported $0.28 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.27 by $0.01. The firm had revenue of $3.90 billion during the quarter, compared to analysts’ expectations of $3.92 billion. Kenvue had a net margin of 6.88% and a return on equity of 21.43%. The company’s revenue was down .4% on a year-over-year basis. During the same period in the prior year, the company posted $0.31 EPS. On average, equities research analysts predict that Kenvue Inc. will post 1.14 earnings per share for the current year.

Kenvue Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Wednesday, February 26th. Shareholders of record on Wednesday, February 12th will be given a $0.205 dividend. The ex-dividend date of this dividend is Wednesday, February 12th. This represents a $0.82 dividend on an annualized basis and a dividend yield of 3.84%. Kenvue’s dividend payout ratio (DPR) is presently 149.09%.

Analysts Set New Price Targets

A number of equities research analysts have issued reports on the stock. Piper Sandler upgraded shares of Kenvue from a “neutral” rating to an “overweight” rating and increased their price objective for the stock from $21.00 to $26.00 in a research note on Monday, January 6th. JPMorgan Chase & Co. lifted their price objective on shares of Kenvue from $24.00 to $25.00 and gave the company an “overweight” rating in a research note on Friday, October 11th. Barclays lowered their price objective on shares of Kenvue from $23.00 to $21.00 and set an “equal weight” rating for the company in a research report on Friday, January 17th. Deutsche Bank Aktiengesellschaft lowered Kenvue from a “buy” rating to a “hold” rating and decreased their price target for the company from $25.00 to $24.00 in a research note on Thursday, December 12th. Finally, UBS Group dropped their price objective on Kenvue from $24.00 to $23.00 and set a “neutral” rating for the company in a research report on Thursday, January 16th. One research analyst has rated the stock with a sell rating, seven have assigned a hold rating and four have given a buy rating to the stock. According to data from MarketBeat.com, Kenvue presently has an average rating of “Hold” and a consensus price target of $23.08.

Kenvue Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.